Toradol and Multiple sclerosis - a phase IV clinical study of FDA data

Summary:

Multiple sclerosis is reported as a side effect among people who take Toradol (ketorolac tromethamine), especially for people who are female, 30-39 old, also take Zanaflex, and have Relapsing-remitting multiple sclerosis.

The phase IV clinical study analyzes which people have Multiple sclerosis when taking Toradol. It is created by eHealthMe based on reports of 8,757 people who have side effects when taking Toradol from the FDA, and is updated regularly.

What is Toradol?

Toradol has active ingredients of ketorolac tromethamine. It is often used in pain. eHealthMe is studying from 9,230 Toradol users. Check the latest studies of Toradol.

What is Multiple sclerosis?

Multiple sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath) is found to be associated with 1,087 drugs and 1,361 conditions by eHealthMe. Check the latest studies of Multiple sclerosis.

On Jul, 11, 2026

8,757 people reported to have side effects when taking Toradol.
Among them, 28 people (0.32%) have Multiple sclerosis.

Among these 28 people:

What is the gender of people who have Multiple sclerosis when taking Toradol? *

female: 89.29 %
male: 10.71 %

What is the age of people who have Multiple sclerosis when taking Toradol? *

What are other drugs people take besides Toradol? *

What are other side effects people have besides Multiple sclerosis? *

Hypoaesthesia (reduced sense of touch or sensation): 8 people, 28.57%
Drug Ineffective: 6 people, 21.43%
Speech Impairment (Adult) (inability to speak (adult)): 5 people, 17.86%
Fall: 4 people, 14.29%
Memory Loss: 4 people, 14.29%
High Blood Pressure: 4 people, 14.29%
Headache (pain in head): 4 people, 14.29%
Pain In Extremity: 4 people, 14.29%
Death: 4 people, 14.29%
Urinary Tract Infection: 3 people, 10.71%

What are the existing conditions these people have? *

Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 11 people, 39.29%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 6 people, 21.43%
Nausea (feeling of having an urge to vomit): 4 people, 14.29%
Thrombosis (formation of a blood clot inside a blood vessel): 4 people, 14.29%
Primary Progressive Multiple Sclerosis (primary progressive inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 3 people, 10.71%
Vitamin B12 Decreased: 2 people, 7.14%
Insomnia (sleeplessness): 2 people, 7.14%
Constipation: 2 people, 7.14%
Diarrhea: 2 people, 7.14%
Eye Movements - Uncontrollable: 2 people, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Toradol and have Multiple sclerosis?

- Check whether Multiple sclerosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Toradol:

Toradol (9,230 reports)

Browse all side effects of Toradol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Multiple sclerosis:

Multiple sclerosis (1,087 drugs)

Browse all the conditions that are associated with Multiple sclerosis:

Multiple sclerosis (1,361 conditions)

Related publications that referenced our studies

Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on ketorolac tromethamine (the active ingredients of Toradol) and Toradol (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.